A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Approximately 18 women will be enrolled in this single-center, double-blind, randomized Phase I study to assess vaginal tissue and fluid levels, plasma levels and pharmacokinetics of dapivirine (TMC120) gel, which will be applied for 10 consecutive days in 18 healthy HIV-negative women ages 18 to 50. Volunteers will be randomized in a 1:1:1 ratio to receive 2.5mL dapivirine vaginal microbicide gel at one of three concentrations.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Willing to participate and sign and informed consent form.
Willing to be tested for HIV and to use an experimental vaginal gel.
Willing to use a reliable form of contraception during the study.
Willing to undergo pelvic examinations with colposcopy according to the protocol throughout the study.
Normal cervical assessment.
Willing to abstain from using any vaginal product (other than the study product).
Willing to be sexually abstinent from Day 1 until completion of study product use on Day 10.
Currently pregnant or breast-feeding.
Currently has any clinically detectable abnormality on the vulva, vaginal walls or cervix.
Currently has laboratory confirmed gonorrhea, chlamydia, trichomonas or syphilis, has Genital Ulcer Disease (GUD) or vaginal candidiasis symptoms; or has an HSV-2 lesion as indicated by clinical diagnosis or laboratory test.
Symptomatic bacterial vaginosis (BV) and unwilling to undergo treatment.